Long-Acting Beta Agonists Enhance Allergic Airway Disease

@inproceedings{Knight2015LongActingBA,
  title={Long-Acting Beta Agonists Enhance Allergic Airway Disease},
  author={J Morgan Knight and Garbo Mak and Joanne A Shaw and Paul Porter and Catherine McDermott and Luz E Roberts and Ran You and Xiaoyi Yuan and Valentine Ongeri Millien and Yuping Qian and Li-zhen Song and Vincent Frazier and Choel Kim and Jeong Joo Kim and Richard A. Bond and Joshua D. Milner and Yuan Zhang and Pijus Kumar Mandal and Amber U. Luong and Farrah Kheradmand and John S. McMurray and David B Corry and Bernhard Ryffel},
  booktitle={PloS one},
  year={2015}
}
Asthma is one of the most common of medical illnesses and is treated in part by drugs that activate the beta-2-adrenoceptor (β2-AR) to dilate obstructed airways. Such drugs include long acting beta agonists (LABAs) that are paradoxically linked to excess asthma-related mortality. Here we show that LABAs such as salmeterol and structurally related β2-AR drugs such as formoterol and carvedilol, but not short-acting agonists (SABAs) such as albuterol, promote exaggerated asthma-like allergic… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 6 times over the past 90 days. VIEW TWEETS